A comprehensive analysis of the pharmacodynamic effects of nt100, a novel G-CSF

NT100 is a novel rhG-CSF being developed specifically for use in the indications of repeated implantation failure and recurrent miscarriage. The hypothesized mechanism of action in these indications is promotion of maternal-fetal tolerance. Because maternal-fetal tolerance encompasses a series of systemic changes affecting many cell types, analyses of individual proteins or cell types may not provide a complete picture. We therefore undertook a comprehensive flow cytometric analysis of more than 50 immune cell subsets to gain a broader view of NT100’s systemic effects.